Floatz logo

PARSATUZUMAB

Solid Cancers

Genentech, Inc.monoclonal_antibodyPhase 1Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Solid Cancers cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Genentech, Inc.
Phase 2B
Irinotecan
Hoffmann-La Roche
Phase 1B
(+)-VINCRISTINE
Hoffmann-La Roche
Phase 1B
Tunlametinib
Tianjin Medical University Second Hospital
Phase 2CCC
Gdc-0449
Genentech, Inc.
Phase 1CCC

View all 49 →

Same molecule, other indications

PARSATUZUMAB is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →